Nuevocor develops NVC-001, a mechanobiology‑focused genetic medicine that uses gene‑editing to correct LMNA mutations in cardiomyocytes, restoring nuclear envelope function and stabilizing heart structure. The therapy aims to provide a disease‑modifying alternative to cardiac transplant for patients with LMNA‑related dilated cardiomyopathy, targeting specialty cardiac centers worldwide.
Funding
$45M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
6OFounders
Product
Problem
Patients with rare, aggressive cardiomyopathies such as LMNA‑related dilated cardiomyopathy have no disease‑modifying therapies, leaving cardiac transplant as the only viable option despite its high cost and limited availability.
Solution
Nuevocor is developing a mechanobiology‑focused genetic medicine, NVC‑001, that directly addresses the underlying mechanical defects of LMNA‑related dilated cardiomyopathy. The therapy delivers a targeted gene‑editing construct designed to restore normal nuclear envelope function in cardiac muscle cells, thereby stabilizing heart structure and preventing progressive failure. By leveraging advanced delivery vectors and precision editing, NVC‑001 aims to provide a disease‑modifying alternative to transplantation. The company collaborates with leading academic and clinical partners worldwide to accelerate preclinical validation and clinical testing, positioning the product for rapid entry into specialized cardiac care pathways.
Target Audience
Primary customers are specialty cardiac centers and cardiologists treating patients with LMNA‑related dilated cardiomyopathy, as well as research institutions pursuing mechanobiology‑based therapies for rare heart diseases.
Features
- Gene‑editing platform engineered to correct LMNA mutations in cardiomyocytes
- Delivery system optimized for cardiac tissue uptake and sustained expression
- Mechanobiology‑centric design that restores nuclear-cytoskeletal integrity to improve heart contractility
- Preclinical data demonstrating reversal of ventricular dilation and functional improvement
- Integrated biomarker program to monitor mechanical remodeling and therapeutic response
- Collaborative development model with leading cardiology centers in the US, Europe, and Asia